{
  "slug": "eyenuk",
  "name": "Eyenuk",
  "description": "Eyenuk provides the first and only FDA 510(k)-cleared autonomous AI (powered by EyeArt) that detects vision-threatening diabetic retinopathy. The solution offers immediate health insights through non-invasive retinal imaging, designed for early detection, triage, and monitoring of eye diseases like DR, AMD, and glaucomatous signs without requiring specialists for initial screening.",
  "url": "https://optimly.ai/brand/eyenuk",
  "websiteUrl": "https://eyenuk.com/",
  "logoUrl": "https://logo.clearbit.com/eyenuk.com",
  "baiScore": 52.5,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "AI-powered Medical Imaging & Diagnostics Software",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-09-21T18:15:14.979Z",
  "verifiedVitals": {
    "website": "https://eyenuk.com",
    "category": "Healthcare AI, Medical Technology, Ophthalmology",
    "what_it_does": "Eyenuk provides an autonomous AI system, EyeArt, for the detection of vision-threatening diabetic retinopathy (vtDR) and more than mild diabetic retinopathy (mtmDR). The system also has a Class IIb CE mark for the detection of DR, AMD, and glaucomatous signs. It offers solutions for screening, triage, and monitoring, enabling early detection and management of eye diseases.",
    "primary_audience": "Primary care, endocrinology, optometry, ophthalmology, and healthcare systems.",
    "core_product": "EyeArt",
    "named_competitors": null
  },
  "intentTags": {
    "problemIntents": [
      "Manual screening methods for diabetic retinopathy cannot keep pace with demand",
      "Vision loss caused by undetected diabetic retinopathy",
      "Lack of access to diabetic retinopathy screening, especially in rural areas",
      "Inefficiency and administrative burden in clinical workflows",
      "High costs associated with blindness and delayed care",
      "Ungradable image bottleneck in traditional retinal screening",
      "Delays in specialist referrals and patient care"
    ],
    "solutionIntents": [
      "Autonomous AI for early detection of vision-threatening diabetic retinopathy",
      "Non-invasive retinal exams without pupil dilation",
      "Rapid and accurate diagnostic results (in seconds)",
      "Point-of-care screening without the immediate need for a specialist",
      "Streamlined workflow for screening, triage, and monitoring of eye diseases",
      "Improved operational efficiency through seamless EHR integration and on-demand analytics",
      "Enhanced financial health for providers by maximizing value-based care bonuses and enabling CPT billing (92229)",
      "Clinical innovation with a multidisease platform for DR, AMD, glaucoma, and systemic health biomarkers",
      "Increased accessibility to diabetic retinopathy screenings for patients",
      "Optimization of specialist resources by filtering normal exams"
    ],
    "evaluationIntents": [
      "FDA 510(k)-cleared for autonomous AI detection of mtmDR and vtDR",
      "Class IIb CE mark (EU MDR) for DR, AMD, and glaucomatous signs detection",
      "High sensitivity (96% for mtmDR, 97% for vtDR) and specificity (88% for mtmDR, 90% for vtDR)",
      "SOC 2 Type 2 attestation, HIPAA, GDPR, and ISO 13485:2016 (MDSAP) compliant",
      "Compatible with multiple retinal camera models from major manufacturers",
      "Clinical evidence and testimonials validating efficacy and efficiency"
    ]
  },
  "businessProfileClaims": [],
  "timestamp": 1790156603076
}